Against the backdrop of surging global demand for mRNA vaccines, Contract Development and Manufacturing Organizations (CDMOs) are facing unprecedented challenges in flexible production. From COVID-19 vaccines to personalized cancer vaccines, CDMO enterprises need to rapidly switch production lines, adapt to multi-variety small-batch production, while meeting stringent regulations and quality requirements. Below are core strategies and practical case studies addressing this challenge.
1. Modular Production and Automation Technology Break Traditional Bottlenecks
CDMO companies have revolutionized traditional fixed production line limitations by introducing modular production facilities and automation technology. For instance, an Indian CDMO giant purchased 50 sets of CEM Liberty PRO™ fully automatic polypeptide synthesis systems, transforming peptide production from large reactors into flexible small unit modules. Equipment can be freely combined according to order needs within the cGMP framework, achieving seamless switching between large-scale single-product production and small-scale diversified production. The system utilizes focused microwave electromagnetic technology and no-wash processes, increasing synthesis speed by 5-20 times and reducing reagent usage by 95%, significantly lowering production costs and risks.
Eanovo Gene & Cell Tech domestically built a highly integrated T-BLOC modular GMP facility, achieving industry-leading daily volumetric productivity exceeding 8g/L through the integration of continuous flow bioprocess (HiCB) platforms. Its 2000L production line supports simultaneous production of multiple products and avoids cross-contamination through disposable technologies, significantly shortening the cycle from laboratory to commercial production. The intelligent filling linkage line introduced by Dongtai Pharmaceutical, equipped with six-axis robotic arms and automatic weighing systems, realizes the full automation of vial filling, stoppering, and capping, improving production efficiency by over 30% and ensuring product quality through 100% online inspection.
2. Supply Chain and Digital Management Optimize Resource Allocation
To address raw material fluctuations and logistics disruptions, CDMO companies have strengthened supply chain resilience. Boehringer Ingelheim maintained active pharmaceutical ingredient capacity at over 70% during the pandemic through increased inventory of key materials, dynamic scheduling, and government collaboration. MabPlex's WMS system achieved full-process intelligent control of more than 2400 types of GMP materials and nearly 20,000 types of R&D materials, processing over 5500 documents daily, improving data flow efficiency by 60%, significantly optimizing warehouse management and production scheduling.
Digital transformation extends throughout the entire production process. Porton, in PROTAC drug development, used real-time process data collection and tracking systems to achieve precise control from gram-level to 50 kg-scale production, completing delivery within six months to support client IND applications. This end-to-end digital management not only enhances efficiency but also provides solid support for parallel projects.
3. Quality Control and Regulatory Compliance Provide Dual Assurance
Given the high sensitivity and personalized production demands of mRNA vaccines, CDMO companies adopt disposable technologies and strict operating procedures to mitigate cross-contamination risks. Merck’s Pellicon® Capsule disposable ultrafiltration membrane pack, adopted by a renowned global mRNA manufacturer, bypasses the difficulties of traditional membrane cleaning validation, ensuring sterility and stability in the production process through closed design and Gamma irradiation pre-sterilization. In personalized cancer vaccine production, each patient requires separate batch production, minimizing nucleic acid residue risk through segregated areas, dedicated equipment, and enhanced cleaning validation.
Regarding regulatory compliance, companies like Boehringer Ingelheim established comprehensive quality management systems covering preclinical research to commercial production, strictly adhering to international standards such as ICH Q7, Q9, and passing audits by FDA, EMA, and others. Eanovo Gene & Cell Tech embedded risk-based phase-wise CMC strategies during process development to ensure full lifecycle compliance from early-stage R&D to market entry.
4. Technological Cooperation and Ecological Synergy Accelerate Innovation Conversion
CDMO companies are building open ecosystems through deep cooperation to tackle complex technical challenges. Porton collaborates with domestic and foreign pharmaceutical companies on PROTAC drug development, optimizing synthetic routes and crystallization processes to keep palladium residues below 2ppm, successfully supporting multiple IND submissions. Osmed Medical Device uses a "flexible production resource pool" model, integrating plant, equipment, and compliance resources to help innovative enterprises reduce initial investments by 90%, accelerating product launches.
In personalized vaccine fields, CDMOs and biotechnology companies collaborate closely. For example, Beijing LiKang Bio’s “LK101 Injection” completed clinical applications through CDMO partnerships, while Moderna and Merck’s Phase III trials of mRNA cancer vaccines rely on customized production support from CDMOs. This industry-academia-research collaboration model is extending mRNA technology from infectious diseases to broader applications such as oncology and genetic disorders.
5. Future Trends: Intelligent and Green Manufacturing Coexist
With the development of Industry 4.0 and synthetic biology technologies, CDMO facilities are upgrading towards intelligence and sustainability. Dongtai Pharmaceutical’s smart workshop improves both production efficiency and safety through AI quality warning systems and robotic operations. Additionally, devices like CEM Liberty PRO™ practice green manufacturing concepts by reducing reagent consumption and waste emissions. The policy guidance from the Ministry of Industry and Information Technology in 2025 encourages CDMO companies to integrate digital tools and modular capacities to meet future multi-variety and rapid iteration market demands.
Conclusion
The explosion of mRNA vaccines not only tests CDMO companies' capacity expansion capabilities but also promotes their overall innovation in technology, management, and ecological cooperation. Through modular production, digital management, supply chain resilience, and strict quality control, CDMOs are reshaping the paradigm of biopharmaceutical manufacturing, providing flexible and efficient solutions to global health crises. This transformation not only accelerates the accessibility of vaccines and innovative drugs but also lays a solid foundation for the industry to respond to public health emergencies and personalized medical needs in the future.
Copyright © 2025 Senwo International
